Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 28

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 28
---
 | ​                                      | ​ | ​ |       ​ | ​ | ​ | ​ | ​ | ​ | 24,000 | ​ | ​ | ​ | ​ | ​ | 12,000 | ​ | ​ |     |   |
| ​                   | Nominating, Governance and Sustainability | ​ | ​                                      | ​ | ​ |       ​ | ​ | ​ | ​ | ​ | ​ | 18,000 | ​ | ​ | ​ | ​ | ​ |  9,000 | ​ | ​ |     |   |
| ​                   | Science and Technology                    | ​ | ​                                      | ​ | ​ |       ​ | ​ | ​ | ​ | ​ | ​ | 18,000 | ​ | ​ | ​ | ​ | ​ |  9,000 | ​ | ​ |     |   |
| ​                   | Initial Equity Grant―Stock Options(3)     | ​ | ​                                      | ​ | ​ | 450,000 | ​ | ​ | ​ | ​ | ​ |      ​ | ​ | ​ | ​ | ​ | ​ |      ​ | ​ | ​ |     |   |

(1) All cash retainers are paid in advance in quarterly installments, subject to the director’s continued service on the board. The cash retainers are prorated if necessary. Non-employee directors are also reimbursed for reasonable travel and other expenses in connection with attending board and committee meetings. (2) The stock options and RSUs vest one year from the grant date, subject to the director’s continued service with our Company. Each RSU entitles the director to one share of our common stock. In the event of a change of control or our liquidation or dissolution, 100% of the then unvested stock options and RSUs will immediately vest. Of the $300,000 annual target value, stock options and RSUs each consist of 50% ($150,000 each). (3) The stock options vest monthly over a three-year period, subject to the director’s continued service on the board.

38 | investor.pacira.com

TABLE OF CONTENTS Corporate Governance and Board Matters

DIRECTOR COMPENSATION TABLE The following table sets forth a summary of the compensation earned by our non-employee directors for the year ended December 31, 2024. Dr. Andreas Wicki, a former non-employee director who resigned from the board, effective January 28, 2025, did not accept compensation for serving on our